258 related articles for article (PubMed ID: 19698704)
1. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
[TBL] [Abstract][Full Text] [Related]
2. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
3. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
4. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
5. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
6. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
[TBL] [Abstract][Full Text] [Related]
8. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism.
Elliott E; Atlas R; Lange A; Ginzburg I
Eur J Neurosci; 2005 Sep; 22(5):1081-9. PubMed ID: 16176349
[TBL] [Abstract][Full Text] [Related]
9. Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors.
Wang HH; Li HL; Liu R; Zhang Y; Liao K; Wang Q; Wang JZ; Liu SJ
J Alzheimers Dis; 2010; 21(1):167-79. PubMed ID: 20413892
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
Muyllaert D; Kremer A; Jaworski T; Borghgraef P; Devijver H; Croes S; Dewachter I; Van Leuven F
Genes Brain Behav; 2008 Feb; 7 Suppl 1():57-66. PubMed ID: 18184370
[TBL] [Abstract][Full Text] [Related]
11. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
12. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
13. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
16. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
[TBL] [Abstract][Full Text] [Related]
17. Tau overexpression in transgenic mice induces glycogen synthase kinase 3beta and beta-catenin phosphorylation.
Shim SB; Lim HJ; Chae KR; Kim CK; Hwang DY; Jee SW; Lee SH; Sin JS; Leem YH; Lee SH; Cho JS; Lee HH; Choi SY; Kim YK
Neuroscience; 2007 May; 146(2):730-40. PubMed ID: 17337327
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau.
Nuydens R; Van Den Kieboom G; Nolten C; Verhulst C; Van Osta P; Spittaels K; Van den Haute C; De Feyter E; Geerts H; Van Leuven F
Neurobiol Dis; 2002 Feb; 9(1):38-48. PubMed ID: 11848683
[TBL] [Abstract][Full Text] [Related]
19. Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.
Ishizawa T; Sahara N; Ishiguro K; Kersh J; McGowan E; Lewis J; Hutton M; Dickson DW; Yen SH
Am J Pathol; 2003 Sep; 163(3):1057-67. PubMed ID: 12937146
[TBL] [Abstract][Full Text] [Related]
20. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
Avila J
FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
